These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34714524)

  • 1. Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy.
    McCrimmon RJ; Lamotte M; Ramos M; Alsaleh AJO; Souhami E; Lew E
    Diabetes Ther; 2021 Dec; 12(12):3231-3241. PubMed ID: 34714524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK.
    McCrimmon RJ; Falla E; Sha JZ; Alsaleh AJO; Lew E; Hudson R; Baxter M; Palmer K
    Diabetes Ther; 2021 Dec; 12(12):3217-3230. PubMed ID: 34714523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi.
    Pöhlmann J; Russel-Szymczyk M; Holík P; Rychna K; Hunt B
    Diabetes Ther; 2019 Apr; 10(2):493-508. PubMed ID: 30706364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy.
    Pöhlmann J; Montagnoli R; Lastoria G; Parekh W; Markert M; Hunt B
    Clinicoecon Outcomes Res; 2019; 11():605-614. PubMed ID: 31632108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US.
    Shao H; Alsaleh AJO; Dex T; Lew E; Fonseca V
    Diabetes Ther; 2022 Sep; 13(9):1659-1670. PubMed ID: 35930188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting.
    Drummond R; Malkin S; Du Preez M; Lee XY; Hunt B
    Diabetes Obes Metab; 2018 Oct; 20(10):2371-2378. PubMed ID: 29797389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Efficacy and Safety of Commercially Available Fixed-Ratio Combinations of Insulin Degludec/Liraglutide and Insulin Glargine/Lixisenatide: A Network Meta-analysis.
    Visolyi GÁ; Domján BA; Svébis MM; Péterfi A; Lovász BD; Mészáros S; Horváth VJ; Tabák ÁG
    Can J Diabetes; 2023 Jun; 47(4):368-377. PubMed ID: 36963632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence.
    Raya PM; Blasco FJA; Hunt B; Martin V; Thorsted BL; Basse A; Price H
    Diabetes Obes Metab; 2019 Jun; 21(6):1349-1356. PubMed ID: 30740861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK.
    McCrimmon RJ; Palmer K; Alsaleh AJO; Lew E; Puttanna A
    Diabetes Ther; 2022 Jun; 13(6):1203-1214. PubMed ID: 35543869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S.
    Dempsey M; Mocarski M; Langer J; Hunt B
    Endocr Pract; 2018 Sep; 24(9):796-804. PubMed ID: 30308134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic.
    Kvapil M; Prázný M; Holik P; Rychna K; Hunt B
    Diabetes Ther; 2017 Dec; 8(6):1331-1347. PubMed ID: 29063511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Cost-effectiveness Analysis of iGlarLixi Versus IDegAsp and Appropriate Price Exploration of iGlarLixi for Type 2 Diabetes Mellitus Patients in China.
    Jiang Y; Liu R; Xuan J; Lin S; Zheng Q; Pang J
    Clin Drug Investig; 2023 Apr; 43(4):251-263. PubMed ID: 36943659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature.
    Lisco G; De Tullio A; Guastamacchia E; Triggiani V
    Endocr Metab Immune Disord Drug Targets; 2021; 21(4):626-646. PubMed ID: 32628602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients.
    Wei R; Wang W; Huang X; Qiao J; Huang J; Xing C; Pan Q; Guo L
    Diabetol Metab Syndr; 2023 Aug; 15(1):173. PubMed ID: 37598203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Relative Cost of Control Analysis of IDegLira versus Other Forms of Basal Insulin Intensification in Mexico.
    Garnica-Cuellar JC; Morales-Villegas E; López-Forero CA; Monroy-Cruz B; Pariti B; Deshwal S; Sekharan M; Osorio-Hernández M; García-Appendini IC
    Pharmacoecon Open; 2023 Sep; 7(5):841-849. PubMed ID: 37452964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison.
    Home PD; Aroda VR; Blonde L; Guyot P; Shaunik A; Fazeli MS; Goswami H; Kalra S; Pourrahmat MM
    Diabetes Obes Metab; 2020 Nov; 22(11):2170-2178. PubMed ID: 32627297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China.
    Feng Z; Tong WK; Zhang X; Tang Z
    Front Pharmacol; 2023; 14():1226778. PubMed ID: 37621313
    [No Abstract]   [Full Text] [Related]  

  • 18. Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands.
    Hunt B; Glah D; van der Vliet M
    Diabetes Ther; 2017 Aug; 8(4):753-765. PubMed ID: 28523483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting.
    Hunt B; Mocarski M; Valentine WJ; Langer J
    Diabetes Ther; 2017 Jun; 8(3):531-544. PubMed ID: 28349444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes.
    Valentine V; Goldman J; Shubrook JH
    Diabetes Ther; 2017 Aug; 8(4):739-752. PubMed ID: 28721686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.